ICON Public Limited Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ICLR research report →
Range $105 – $268
Price Chart
About the company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.
- CEO
- Barry Balfe
- IPO
- 1998
- Employees
- 40,200
- HQ
- Dublin, DU, IE
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive multi-month uptrend, trading well above its 200-day average of 146.69 and its 50-day average of 179.01. It remains below the 52-week high of 219.04, so the setup is strong but still short of a full breakout regime.
Street sentiment is firmly constructive: 16 buys, 12 holds, and 2 sells, with a consensus Buy and an average target of 217.5. Recent target revisions were broadly higher across multiple firms, signaling improving confidence in the recovery story.
The company has beaten EPS in 7 of the last 8 quarters, including the latest report, which came in at 2.46 versus 2.40 expected. Next-year EPS estimates are still pointed sharply higher, so shareholders should watch whether margin recovery keeps translating into cleaner execution.
The pattern is net selling, led by multiple discretionary sales from the CEO and a director, while the M-code entries look like exempt award-related activity rather than open-market conviction. With 12 sells and no buys, insiders are trimming into strength rather than adding.
Profitability is modest but improving, with a 2.72% operating margin and 5.26% net margin. Growth remains uneven: revenue fell 2.9% year over year and earnings dropped 63.3%, but free cash flow was strong at $1.21 billion, or 8.30% yield.
ICLR sits in the higher-quality end of life sciences tools and services, where scale and recurring clinical demand matter. The valuation is not cheap, but the market is paying for recovery: the consensus target of 217.5 sits above the current setup and reflects margin rebound expectations.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.99B
- P/E
- 31.92
- Fwd P/E
- 17.65
- PEG
- -1.50
- P/S
- 1.70
- P/B
- 1.57
- EV/EBITDA
- 12.18
- Div Yield
- 0.00%
- Gross Margin
- 21.19%
- Op Margin
- 9.46%
- Net Margin
- 5.45%
- ROE
- 4.85%
- ROIC
- 4.85%
Latest fiscal year · YoY change
- Revenue
- $8.25B-0.4%
- Gross Profit
- $2.18B-10.7%
- Op Income
- $1.01B
- Net Income
- $229.34M-71.0%
- EPS
- $2.92-69.6%
- OCF Growth
- -19.5%
- FCF Growth
- -22.9%
- 52W High
- $219.04
- 52W Low
- $66.57
- 50D MA
- $181.49
- 200D MA
- $147.10
- Beta
- 1.19
- RSI (14)
- 45
- Avg Volume
- 984.49K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ICON said Q3 was a solid step forward, with better mix and cost control driving margin improvement, record net bookings, and management pointing to a clearer path for 2027 growth.· October 28, 2026
- Revenue was just over $2 billion, down 2.9% year over year and down 2.5% constant currency; adjusted EBITDA rose 3% sequentially to $337 million and adjusted EPS was $2.66, up 4% from Q2.
- Adjusted gross margin improved 90 basis points sequentially to 24.7%, and adjusted EBITDA margin expanded 70 basis points to 16.6%.
- Net business wins were a record $3.15 billion, up 51% year over year, with a net book-to-bill of 1.56x; this was the fourth straight quarter above 1.3x.
- Free cash flow was $302 million in the quarter, helped by $340 million of cash from operations and $38 million of capex; ICON repurchased $400 million of shares and ended with $809 million of cash.
- Management narrowed full-year 2026 guidance and said the business now has enough visibility to support possible mid-single-digit revenue growth and higher single-digit earnings growth in 2027, though formal 2027 guidance will come with Q4 results.
Q3 revenue was just over $2 billion, down 2.9% year over year, or down 2.5% on a constant currency basis. Revenue declined 1.9% sequentially from Q2, mainly due to the Symphony divestiture. Adjusted EBITDA increased 3% sequentially to $337 million, with adjusted EBITDA margin at 16.6% (+70 bps sequentially). Adjusted gross margin was 24.7%, up 90 bps from Q2. Adjusted EPS was $2.66, up 4% sequentially; adjusted net income was $206 million. U.S. GAAP net income was $122 million, or $1.58 per diluted share. Free cash flow was $302 million, with $340 million from operations and $38 million of capex. Net business wins were a record $3.15 billion, up 51% year over year, and net book-to-bill was 1.56x; gross business wins rose 27% year over year. For the full year, management raised revenue outlook to the high end of the prior range because pass-through activity is running above prior assumptions. Nigel said full-year 2026 adjusted EBITDA margin is still expected to be roughly 16% to 16.5%. Management also said full-year 2026 adjusted tax rate should be about 17%, and about 18% next year. Cash was $809 million at 9/30/2026, net debt was $2.6 billion, and leverage was 2.0x net debt to trailing adjusted EBITDA. The company completed a $2.15 billion investment-grade bond issuance and used the proceeds to refinance debt. It repurchased $400 million of shares in Q3 at an average price of $170 per share, and the board approved a new $750 million repurchase authorization.
Barry Balfe framed Q3 as another step forward in the recovery story, saying commercial momentum, better mix, and disciplined execution are starting to show up in the P&L. He highlighted strong bookings, improving direct-fee trends, and early signs that ICON’s technology and operating model are changing customer behavior toward outcomes and partnership-based relationships. His tone was confident and constructive, but he repeatedly said 2027 guidance will come later and emphasized execution over promises.
Nigel Clerkin focused on the financial bridge: revenue was just over $2 billion, adjusted EBITDA was $337 million, adjusted gross margin was 24.7%, and adjusted EPS was $2.66. He said the quarter benefited from improved business mix and operating cost control, and that stronger pass-through activity is now expected to push full-year revenue to the high end of the prior range. He also laid out liquidity and capital structure: $340 million of operating cash flow, $302 million of free cash flow, $809 million of cash, $2.6 billion of net debt, 2.0x leverage, and about $200 million of blended annual fixed interest expense after the $2.15 billion refinancing. Capital allocation remained balanced, with $400 million of buybacks in the quarter and a new $750 million authorization.
The most common analyst theme was how to think about direct-fee recovery, pass-through intensity, and how bookings translate into revenue and margin. Management said direct fees were modestly up sequentially and that the real driver of margin improvement is business mix plus cost control; Barry also said a 1.3x trailing 12-month direct-fee book-to-bill versus the prior 1.0x period supports a better revenue trajectory. Analysts also pressed on pricing and AI, and Barry responded that pricing is still competitive, but ICON is increasingly selling efficiency, predictability, and outcomes rather than just rate per hour; he said AI tools are targeted at study design, startup, monitoring, and workflow improvements rather than generic automation. On guidance and margins, Nigel said the company still sees full-year adjusted EBITDA margin in the 16% to 16.5% range, with Q4 SG&A expected to rise, while management said 2027 guidance will come with Q4 results.
The quarter showed several signs that ICON’s recovery is becoming more visible: record net bookings, a 1.56x net book-to-bill, gross margin improvement, and a modest return to direct-fee growth. Management also described broad demand strength across large pharma, midsize pharma, and biotech, while pointing to technology wins and better conversion of pipeline into awards.
Revenue still fell year over year, and management acknowledged that pass-through activity is distorting the top line and making the path to cleaner direct-fee growth hard to read. The company also said pricing remains competitive, some margins depend on pass-through mix, and Q4 SG&A should rise, so near-term earnings progression still depends on execution and the exact revenue mix.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 74.92M
- Float Shares
- 74.87M
of shares held by institutions
452 13F filers
Buy/sell ratio 0.16. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ICLR, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Kevin HernHouse · OK01 | Sell | Aug 14, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Mar 5, 26 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Feb 12, 26 | Filing → |
| John JamesHouse · MI10 | Sell | Sep 4, 24 | Filing → |
| John JamesHouse · MI10 | Buy | Jun 12, 24 | Filing → |
| Kevin HernHouse · OK01 | Sell | Jan 31, 23 | Filing → |
| Kevin HernHouse · OK01 | Buy | May 18, 21 | Filing → |
| Kevin HernHouse · OK01 | Buy | Jul 27, 20 | Filing → |
| Kevin HernHouse · OK01 | Buy | Nov 7, 19 | Filing → |
| Kevin HernHouse · OK01 | Buy | Aug 7, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Artisan Partners Limited Partnership | 8.89M | ▲ 248.70K |
| Fmr LLC | 6.59M | ▲ 1.32M |
| Wellington Management Group Llp | 5.32M | ▼ 592.98K |
| Invesco Ltd. | 4.64M | ▼ 628.24K |
| Harris Associates L P | 4.47M | ▲ 116.83K |
| Brave Warrior Advisors, LLC | 3.15M | ▲ 156.50K |
| Greenhaven Associates Inc | 3.07M | ▼ 31.60K |
| Principal Financial Group Inc | 2.94M | ▼ 13.57K |
| Ruane, Cunniff & Goldfarb L.P. | 2.05M | ▲ 413.48K |
| Dimensional Fund Advisors LP | 1.67M | ▲ 402.31K |
| Trinity Street Asset Management Llp | 1.49M | ▼ 48.09K |
| Massachusetts Financial Services Co | 1.47M | ▼ 635.09K |
Held by 345 ETFs
Biggest fund positions in ICLR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Murray Ciaran | sell | 10,000 |
| Nov 2, 26 | Murray Ciaran | sell | 3,452 |
| Oct 31, 26 | Balfe Barry Edward | other | 9,662 |
| Oct 31, 26 | Balfe Barry Edward | other | 9,662 |
| Nov 2, 26 | Balfe Barry Edward | sell | 1,053 |
| Nov 2, 26 | Balfe Barry Edward | sell | 1,509 |
| Nov 2, 26 | Balfe Barry Edward | sell | 1,224 |
| Nov 2, 26 | Balfe Barry Edward | sell | 1,314 |
| Nov 2, 26 | Balfe Barry Edward | sell | 75 |
| Oct 31, 26 | Lyons Emer | other | 491 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ICLR coverage
Recent articles, reports, and earnings notes.

ICON PLC (ICLR): Recovery Momentum vs. Accounting Risk
ICON is showing real booking and margin recovery, but revenue is still slipping and accounting concerns keep the stock in Hold territory. The setup hinges on whether strong backlog conversion can outpace the company’s earnings reset and balance-sheet leverage.

ICON Public Limited Company (ICLR) climbs 10% after hours
ICON Public Limited Company (ICLR) climbs sharply in after-hours trading ahead of its scheduled Q3 earnings report. The move puts the clinical research company near its 52-week high as investors position for results, guidance, and signs that strong bookings can support the stock’s premium valuation.

ICON PLC (ICLR): Earnings Reset With Recovery Potential
ICON is a high-quality CRO facing a tough earnings reset, but improving bookings and a 1.51x book-to-bill point to a possible recovery. The stock looks fairly valued for now, with execution and margin recovery the key swing factors.
Want a deeper read on ICLR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
10,389 Icon Plc $ICLR Shares Bought by Allspring Global Investments Holdings LLC
defenseworld.net · Nov 15
ICON: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 12
ICON to Participate at Upcoming Investor Conferences
businesswire.com · Nov 10
ROYAL CARIBBEAN ANNOUNCES SUMMER 2028 CARIBBEAN LINEUP ACROSS FOUR ICON CLASS SHIPS AND NEWLY AMPLIFIED VACATIONS
prnewswire.com · Nov 5
ICON Launches FIRECREST AI-Directed Video Engine, Changing the Economics of Site Communications
businesswire.com · Nov 5
What Icon (ICLR) Said on Its Q3 Earnings Call
defenseworld.net · Oct 30
ICON Public Limited Company (ICLR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 28
What Icon (ICLR) Said on Its Q3 Earnings Call
marketbeat.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 17, 2026 · Live quote · Not investment advice